Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO6889678 + ritonavir
- Development stage
- Discontinued
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RO6889678 + ritonavir is an **oral combination drug consisting of RO6889678, a small molecule hepatitis B virus (HBV) capsid inhibitor, and ritonavir, a small molecule CYP3A inhibitor**. Ritonavir is used here to boost systemic concentrations of RO6889678 by inhibiting CYP3A-mediated metabolism. The primary mechanism of RO6889678 is to interfere with HBV capsid formation, preventing viral replication. This combination was developed by Roche for the treatment of hepatitis B virus infection and investigated in healthy volunteers to assess pharmacokinetics, safety, and tolerability, as well as drug-drug interaction potential. According to available sources, **the development status for RO6889678 + ritonavir has been discontinued**[1][7].
- Other names
- RO-6889678 + ritonavirRO6889678/ritonavir
02
Targets
CYP3A4 (Cytochrome P450 3A4)PR (Progesterone receptor)HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on RO6889678 + ritonavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO6889678 + ritonavir.